NeuroOne Medical Technologies Corporation (NMTC)
Market Cap | 24.20M |
Revenue (ttm) | 3.73M |
Net Income (ttm) | -12.80M |
Shares Out | 27.84M |
EPS (ttm) | -0.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 82,239 |
Open | 0.880 |
Previous Close | 0.896 |
Day's Range | 0.805 - 0.896 |
52-Week Range | 0.647 - 2.000 |
Beta | 0.98 |
Analysts | Strong Buy |
Price Target | 2.20 (+153.11%) |
Earnings Date | Aug 12, 2024 |
About NMTC
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to dev... [Read more]
Financial Performance
In 2023, NMTC's revenue was $3.41 million, an increase of 60.73% compared to the previous year's $2.12 million. Losses were -$11.86 million, 18.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NMTC stock is "Strong Buy" and the 12-month stock price forecast is $2.2.
News
![](https://cdn.snapi.dev/images/v1/w/a/press17-2488117.jpg)
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024
![](https://cdn.snapi.dev/images/v1/3/y/press2-2430577.jpg)
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical...
![](https://cdn.snapi.dev/images/v1/w/6/conf17-2424847.jpg)
NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical...
![](https://cdn.snapi.dev/images/v1/b/s/press11-2365217.jpg)
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgic...
![](https://cdn.snapi.dev/images/v1/2/j/press18-2363061.jpg)
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control
![](https://cdn.snapi.dev/images/v1/m/d/press7-2356445.jpg)
NeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.
EDEN PRAIRIE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgic...
![](https://cdn.snapi.dev/images/v1/p/b/press16-2341808.jpg)
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control
![](https://cdn.snapi.dev/images/v1/r/r/press16-2315790.jpg)
NeuroOne® to Participate in the 36th Annual Roth Conference
EDEN PRAIRIE, Minn., March 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...
![](https://cdn.snapi.dev/images/v1/n/n/press13-2291937.jpg)
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn., Feb. 23, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/t/o/press10-2274444.jpg)
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/w/l/conf1-2268004.jpg)
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/j/1/press11-2197179.jpg)
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/s/1/conf16-2188381.jpg)
NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/u/i/press10-2161132.jpg)
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes
![](https://cdn.snapi.dev/images/v1/d/a/press17-2158258.jpg)
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
![](https://cdn.snapi.dev/images/v1/j/2/conf19-2102557.jpg)
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/o/m/conf11-2052363.jpg)
NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...
![](https://cdn.snapi.dev/images/v1/t/e/press6-2022270.jpg)
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/b/m/conf9-2012905.jpg)
NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14
EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
![](https://cdn.snapi.dev/images/v1/o/f/press5-1985091.jpg)
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
EDEN PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options...
![](https://cdn.snapi.dev/images/v1/b/o/press12-1930038.jpg)
NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System
Potential for tran s formative improvement in neurosurgery as f irst known sEEG -guided RF system that records and ablates nervous tissue with the added benefit of temperature control
![](https://cdn.snapi.dev/images/v1/h/e/press10-1895093.jpg)
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery
Evo sEEG electrode used with Zimmer Biomet 's ROSA One ® Brain during procedure at Cleveland Clinic
![](https://cdn.snapi.dev/images/v1/d/8/press2-1886137.jpg)
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical...
![](https://cdn.snapi.dev/images/v1/n/5/conf2-1885731.jpg)
NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical...
![](https://cdn.snapi.dev/images/v1/g/x/press10-1882235.jpg)
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic
Evo sEEG electrode s used for brain mapping in epilepsy surgery